Radius Health, Inc. (RDUS)

Market Cap	847.45M
Revenue (ttm)	223.36M -10.2%
Net Income	-68.63M
EPS	-1.45
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	30.00
Day's Range	n/a
52-Week Range	10.57 - 30.04
Beta	1.01
Analysts	Hold
Price Target	22.00 (-26.64%)
Earnings Date	Jul 1, 2025

About RDUS

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. Its commercial product includes BINOSTO, TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It also develops abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901)...

• Industry: Steel
• Sector: Materials
• IPO Date: Nov 15, 1993
• Employees: 293
• Stock Exchange: NASDAQ
• Ticker Symbol: RDUS
• Website: https://radiuspharm.com

Financial Performance

In 2021, Radius Recycling's revenue was $229.97 million, a decrease of -3.63% compared to the previous year's $238.65 million. Losses were -$70.18 million, -35.74% less than in 2020.

Analyst Summary

According to one analyst, the rating for RDUS stock is "Hold" and the 12-month stock price target is $22.0.

Price Target

$22.0

(-26.64% downside)

Analyst Consensus: Hold